Codex­is cuts 25% of staff, slash­es drug pro­grams while dou­bling down on RNAi tech

Last year
People
R&D

FDA ap­proves Dai­ichi Sanky­o's new first-line AML drug quizar­tinib with boxed warn­ing for heart dis­or­ders

Last year
FDA+

Ex­clu­sive: Af­ter Cure­Vac, Ig­or Splaws­ki moves to RTW stealth start­up; Lyn­dra's Jes­si­ca Ballinger adds CEO ti­tle amid ...

Last year
Peer Review

Af­ter sev­en pa­tient deaths, ADC gets par­tial hold and de­cides to stop Zyn­lon­ta tri­al

Last year
R&D
FDA+

Turn­stone Bi­o­log­ics rides biotech's IPO train in Fri­day de­but

Last year
Financing
Startups

Scoop: CNS biotech Map­Light Ther­a­peu­tics eyes $175M raise for PhII clin­i­cal tri­als in schiz­o­phre­nia, autism and ...

Last year
Financing
Startups

Grail pushed a more re­stric­tive em­ploy­ee ar­bi­tra­tion agree­ment short­ly be­fore law­suits

Last year
Pharma
Law

Sen­ate health com­mit­tee ad­vances pan­dem­ic pre­pared­ness reau­tho­riza­tion bill

Last year
Law

Hori­zon adds 'se­vere hear­ing im­pair­men­t' warn­ing to block­buster's la­bel

Last year
FDA+

Pas­sage Bio lays off 26% of staff, lets two ex­ec­u­tives go a year af­ter down­siz­ing, lead­er­ship shuf­fle

Last year
People
Cell/Gene Tx

FTC cau­tions against re­ly­ing on its past PBM ad­vo­ca­cy as in­dus­try push­es back

Last year
Pharma
FDA+

J&J plans to ap­peal $18.8M ver­dict in Cal­i­for­nia ba­by pow­der can­cer case

Last year
Pharma

San­doz to in­vest $90M in Slove­nia site that will pro­duce biosim­i­lars

Last year
Pharma

Pfiz­er set­tles trade se­crets case with com­pa­ny found­ed by ex-em­ploy­ees

Last year
Pharma
Law

Man­u­fac­tur­ing roundup: Ac­tivist in­vestor re­port­ed­ly takes stake in Catal­ent; ProKid­ney caps off pur­chase of NC ...

Last year
Manufacturing

FDA re­ports short­age of No­vo Nordisk's weight loss drug Sax­en­da

Last year
Pharma
Manufacturing

J&J down­sizes in­fec­tious dis­ease and vac­cine pipeline, cut­ting he­pati­tis B pro­grams

Last year
R&D
Pharma

Just two years af­ter launch, neu­ro start­up Eliem goes hunt­ing for busi­ness al­ter­na­tives

Last year
Startups

BioN­Tech inks can­cer deal with Chi­nese biotech; Eikon, CASI buy Cleave Ther­a­peu­tics’ as­sets

Last year
News Briefing

Vir’s GSK-al­lied flu pre­ven­tion an­ti­body fails PhII, sink­ing shares and late-stage hope

Last year
R&D

De­spite Dem op­po­si­tion, House com­mit­tee ad­vances pan­dem­ic pre­pared­ness bill sans drug short­age pro­vi­sions

Last year
Pharma
FDA+

Tor­na­do se­vere­ly dam­ages Pfiz­er's large ster­ile in­jectable plant in North Car­oli­na

Last year
Pharma
Manufacturing

Fol­low­ing Dupix­ent’s rise, Sanofi heads down­stream in im­munol­o­gy for $125M small mol­e­cule pact with Re­cludix

Last year
Financing
Startups

Fa­heem Has­nain gets a $212M stake to­geth­er for his big PhI­II gam­ble — here’s why in­vestors are let­ting it ride

Last year
Deals
Bioregnum
First page Previous page 308309310311312313314 Next page Last page
A service from the Financial Times